UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market

UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market

Source: 
Endpoints
snippet: 

Long a quiet player in the R&D game, UCB made a splash last fall when they announced that their experimental psoriasis drug bimekizumab had defeated J&J’s blockbuster Stelara in a Phase III trial. It was the first of three Phase IIIs meant to launch the candidate into a crowded market dominated by some of the industry’s biggest drugmakers. The second announcement came two months later with a win over AbbVie’s Humira.